DAVID I. MACHT, M.D., F.A.C.P.; WILTON C. HARDEN, PH.D.
This content is PDF only. Please click on the PDF icon to access.
Methylthionine chloride, or methylene blue, is recognized by the United States Pharmacopoeia but its administration has hitherto been only by mouth. Recently, however, considerable publicity has been given its intravenous use in cases of cyanide and carbon monoxide poisoning. This therapeutic application of the dye has been the direct result of the most interesting laboratory investigations of Matilda M. Brooks1,2,3,4 and clinical reports of J. C. Geiger.5,6
The value of methylene blue in the treatment of cyanide poisoning has been described by earlier writers. Thus, Sahlin7 demonstrated its antidotal action in 1926, and Eddy8,9 also found that methylene blue
MACHT DI, HARDEN WC. TOXICOLOGY AND ASSAY OF METHYLENE BLUE*. Ann Intern Med. 1933;7:738–745. doi: https://doi.org/10.7326/0003-4819-7-6-738
Download citation file:
Published: Ann Intern Med. 1933;7(6):738-745.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use